Tuesday 28th June 2022
On 29th June, Scleroderma & Raynaud’s UK will open applications for the Olive Ayoub Intermediate to Late-Stage Post-doctoral Research Fellowship, which will enable one exceptional, non-tenured post-doctoral researcher to transition from postdoc to research leader in the field of scleroderma.
Friday 24th June 2022
A new US study has found that scleroderma patients who test positive for ‘anti-Th/To antibodies’ are at higher risk of developing pulmonary hypertension (PH) in comparison to other patients, which could enable the earlier detection and more effective management of one of scleroderma’s most serious complications.
Friday 17th June 2022
Both of Alison's daughters have scleroderma, and having experienced the lack of understanding around the condition, she set out to help SRUK create a guide to scleroderma for schools.
Wednesday 8th June 2022
Yesterday saw the launch of the Innovative Medicines Fund (IMF) - a scheme which will give NHS patients living in England, including those with rare diseases like Scleroderma, the chance to have ‘early’ access to cutting-edge treatments offering them the best chances of a longer and healthier life.
Thursday 26th May 2022
A British man has become the first Scleroderma patient to receive a double hand transplant for the condition, giving him a new lease of life and prompting hope for many of those most severely affected by the condition.
Tuesday 10th May 2022
New research suggests the ‘VEDOSS’ Criteria could be used to accurately predict which individuals living with Raynaud's are likely to progress to Systemic Sclerosis, prompting further hope regarding the early detection and treatment of the condition.
Friday 22nd April 2022
SRUK co-funds a MRC Clinical Research Training Fellowship to advance research into treatments for interstitial lung disease.
Wednesday 20th April 2022
Ongoing research towards developing new treatments and therapies has a cumulative effect in improving quality of life, but can the problem be addressed directly?
Friday 25th March 2022
On the 17th March 2022 the UK’s Medicine and Health products Regulation Agency (MHRA) approved a new drug, Evusheld, for the prevention of COVID-19 infection.
Thursday 10th March 2022
Can you imagine a future where we will be able to eliminate trial and error in prescribing medications by predicting the best treatment for a person’s scleroderma before they even receive it! The winning proposal of the SRUK/ WSF Stratified Medicine of the Future Award aspires to make this a reality.
